Table 2 Overview metabolic and combined response evaluation to immunotherapy
From: PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Criteria (year) [reference] | Modality | Categories | |||
|---|---|---|---|---|---|
Complete response | Partial response | Stable disease | Progressive disease | ||
EORTC (1999) [31] | PET | • Reduction of 18F-FDG uptake to background levels | • ≥ 15% reduction of 18F-FDG uptake | • Neither CR, PR, nor PD | • ≥ 25% increase in 18F-FDG uptake |
PERCIST (2009) [33] | PET | • Reduction of 18F-FDG uptake to the level of background blood pool | • ≥ 30% reduction in SUL peak • Minimum of 0.8 SUL units of measurable lesions | • Neither CR, PR, nor PD | • > 30% increase in SUL peak • Minimum of 0.8 SUL units of measurable lesions |
PECRIT (2017) [34] | PET/CT | • Disappearance of all metabolically active tumours and TL • SAD reduction target lymph nodes < 10 mm • No new lesions | • ≥ 30% reduction in SUL peak • ≥ 30% decrease in TL diameter sum | • Neither CR, PR, nor PD | • > 30% increase in SUL peak • Or new metabolically active lesion • ≥ 20% increase in target lesion diameter (minimum 5 mm) • Or new lesions |
PERCIMT (2018) [35] | PET/CT | • Complete resolution of all 18F-FDG-avid lesions • No new FDG avid lesions | • Complete resolution of some 18F-FDG-avid lesions • No new 18F-FDG-avid lesions | • Neither CR, PR, nor PD | • ≥ 4 new lesions with ≤ 10 mm functional diameter • Or three or more new lesions with > 10 mm functional diameter • Or two or more new lesions with > 15 mm functional diameter |